(EVO) Evotec SE BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(EVO) Evotec SE Complete Analysis Pack
Visual. Strategic. Downloadable.
This Evotec SE BCG Matrix helps you understand how the company’s products or business units are positioned across Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Neuroscience and CNS pipeline
Evotec’s neuroscience and CNS pipeline is a Star because it sits in a high-need market with long, costly trials and strong partner interest. In 2024, Evotec reported €797.4 million in Group revenue, and CNS assets can help support repeat funding and multi-year deals. That mix of scale, scarcity, and partnership value makes the segment strategically important.
Metabolic disease and diabetes work
Evotec SE targets metabolic disease and diabetes, a market with 589 million adults living with diabetes worldwide in 2024, projected to 853 million by 2050. That scale supports long-term pharma demand and multiple partnered programs. This makes the segment a clear Star candidate, because one successful asset can be copied across several programs.
Oncology discovery programs
Oncology discovery programs are a Star for Evotec SE because the area sits in one of pharma’s biggest R&D pools and still draws frequent partnering. The company can keep growing share by pairing its platform-led discovery with translational support, which helps move targets faster into clinic-ready programs. In 2025, oncology remained a top spend area for large biopharma, keeping demand for external innovation high.
Biologics and protein production platform
Biologics still command a large share of high-value drug development, so Evotec SE’s protein production platform fits a durable demand pool. Its advanced discovery model lets Evotec sell more partnered work as biologics pipelines grow. That makes this a classic "Star": strong market pull plus room to scale.
- High demand across pharma and biotech
- Supports partner-funded, higher-value work
- Scales with biologics pipeline growth
Global partnered R&D engine
Evotec, founded in 1993, runs a partner-led R&D platform, not a single-drug model. That makes the global partnered R&D engine a Star when demand for outsourced discovery is rising, because the same platform can serve many therapeutic areas and deal types. In FY2024, Evotec reported revenue of about €797 million.
- Partner-led, scalable R&D model
- Serves multiple therapeutic areas
- Recurring demand supports growth
Evotec’s Star R&D Areas Tap Big Pharma Demand
Evotec SE’s Stars are partner-led R&D areas with strong pharma demand, especially CNS, oncology, biologics, and metabolic disease. In FY2024, Company Name reported €797.4 million revenue, so these programs help turn external demand into repeat deal flow. Diabetes alone had 589 million adults worldwide in 2024, showing the scale behind the metabolic pool.
| Star area | Why it fits | Data point |
|---|---|---|
| CNS | High unmet need | Long, costly trials |
| Oncology | Heavy R&D spend | 2025 pharma interest stayed high |
| Metabolic | Huge patient base | 589 million adults with diabetes |
What is included in the product
Detailed Word Document
Evotec SE BCG Matrix: concise quadrant analysis of portfolio units, growth prospects, cash generation, and divest/ निवेश signals.
Editable Excel File
Evotec SE BCG Matrix for a quick, clear view of each unit’s growth and share position
Reference Sources
Provides a credible source trail for Evotec SE that helps decision-makers verify assumptions fast and trust the analysis.
Cash Cows
Bayer AG alliance
Bayer is one of Evotec SE’s named strategic collaborators, and Bayer’s €46.6bn 2024 sales base supports repeat demand for outsourced R&D work. These large-pharma ties are usually service-led, recurring, and tied to long programs, so cash flow tends to be steadier than in early-stage deals. That makes the Bayer AG alliance fit a classic Cash Cow profile once the relationship is mature and embedded.
Lilly collaboration
Lilly is a major global pharma partner for Evotec SE, and the collaboration fits BCG cash cows because mature work can generate steady fee income with little extra sales spend. Eli Lilly reported 2024 revenue of $45.0 billion and R&D of $11.9 billion, so the partner has the scale to keep funded programs moving. In a weak-growth setting, this kind of repeat, lower-capex income is a solid cash contributor.
Novo Nordisk A/S partnership
Novo Nordisk A/S is a cash cow partner for Evotec SE because its metabolic franchise is mature and scaled, with FY2024 revenue of DKK 290.4bn and operating profit of DKK 128.3bn. The collaboration can bring steady research fees from a well-funded therapeutic area. That makes the tie-up more about disciplined delivery than market creation.
Pfizer Inc. partnership
Pfizer is a large, established pharma partner for Evotec SE, so this cash-cow relationship can support recurring discovery and development revenue with low selling effort. Pfizer reported FY2024 revenue of $63.6 billion and R&D spend of $10.8 billion, which shows the scale of its pipeline demand and why such contracts can steady operating cash flow.
- Large, recurring client base
- Low marketing cost per contract
- Supports stable cash generation
- Backed by Pfizer's $63.6B FY2024 revenue
Bristol Myers Squibb and Takeda alliances
Bristol Myers Squibb and Takeda are two large, established pharma partners in Evotec SE’s alliance base, and that matters because big-name repeat collaborations can fund R&D without Evotec building consumer demand or sales reach. This fits a Cash Cow profile: steadier milestone, service, and research revenue with lower volatility than asset-heavy drug launches.
- Large pharma partners
- Repeatable research funding
- Lower market-share risk
- Stable cash generation
Evotec’s Cash Cows: Big Pharma Partnerships Drive Steady Fee Income
Evotec SE’s Cash Cows are mature pharma ties that can bring repeat fee income with low sales spend. Bayer, Lilly, Novo Nordisk, Pfizer, Bristol Myers Squibb, and Takeda all fit this role because their large R&D budgets keep programs funded. Pfizer posted $63.6bn FY2024 revenue, while Lilly reported $45.0bn and Novo Nordisk DKK 290.4bn, backing steady cash flow.
| Partner | FY2024 data | Why Cash Cow |
|---|---|---|
| Pfizer | $63.6bn revenue | Repeat funded work |
| Lilly | $45.0bn revenue | Stable fee income |
Full Version Awaits
Evotec SE Reference Sources
The Evotec SE BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No placeholders, no demo pages—just the full, ready-to-use report. Download it instantly and use it for analysis, presentations, or strategic planning. What you preview is what you get.
Dogs
Pain management programs
Pain is listed among Evotec SE’s therapeutic areas, but the Company does not disclose a dominant branded asset or any marketed pain product. With no visible product revenue, share is effectively 0% and growth capture is limited. That makes pain a weak BCG position today, unless a partner advances it into the clinic or market.
Respiratory condition programs
Respiratory condition programs sit inside Evotec SE's broad research scope, but no flagship commercial franchise is disclosed for this area. In BCG terms, that means Evotec's visible market share here is low, so the unit fits Dogs better than Stars or Cash Cows. Unless partnering depth and disclosed program value rise, it remains a low-priority line.
Women’s health programs
Women’s health programs sit inside Evotec SE’s R&D mix, but they do not yet look like a major standalone revenue driver. With no marketed product, the segment has low share and limited near-term scale, which is why it fits the Dog bucket in BCG terms.
That said, if one program reaches clinic or licensing traction, the profile can change fast. Until then, the unit stays capital-light in revenue terms and weak on cash generation versus Evotec SE’s bigger platforms.
Standalone legacy internal assets
Evotec SE’s Dogs are its standalone legacy internal assets: older, unpartnered programs with little outside validation and weak chance of near-term value creation. In a business where partnerships drive most economics, these assets can sit on the balance sheet without scaling; Evotec reported FY2025 revenue of about €796 million, but standalone asset-level returns remain hard to prove from disclosed data.
- Low market share
- Weak external validation
- Capital tied up
- Low return potential
Low-scale niche discovery work
Low-scale niche discovery work fits the Dog box at Evotec SE because small programs rarely change group results fast enough. In 2024, Evotec SE generated about €797 million in revenue, so weak, unpartnered lines are too small to move the needle by end-2025. If growth stays modest and no strong partner funds the asset, returns stay thin, so pruning or divestiture is rational.
- Small scale means low strategic impact.
- No partner support keeps returns weak.
- Review, prune, or sell these assets.
Evotec’s Dogs: Low-Value, Capital-Light, and Still Unproven
Evotec SE’s Dogs are small, unpartnered pain, respiratory, and women’s health assets with no disclosed marketed product and near-zero share. FY2025 revenue was about €796 million, but these lines did not show clear cash pull. Without partner funding or clinical traction, they stay low-value and capital-light.
| Dog signal | FY2025 note |
|---|---|
| Market share | Near zero |
| Revenue impact | Not disclosed |
| External validation | Weak |
Question Marks
CONBA Pharmaceutical Co. Ltd. collaboration
CONBA Pharmaceutical Co. Ltd. gives Evotec SE access to China, a market serving 1.4 billion people and still expanding. But Evotec’s disclosed share here is not dominant, so the fit is a Question Mark, not a Star. Upside is real, yet turning it into scale needs strong adoption, clear milestones, and steady execution.
Zhejiang JingXin Pharmaceutical Co. Ltd. collaboration
Zhejiang JingXin Pharmaceutical Co. Ltd. gives Evotec SE a real Asia growth angle, but it is still a Question Mark because the value sits in future optionality, not proven scale. The partnership-led model means Evotec has reach, yet not enough market control to call it a leader. It needs funded execution and measurable data to convert pipeline promise into recurring impact.
Kazia Therapeutics collaboration
Kazia Therapeutics sits in oncology, a market that keeps expanding, but Evotec SE still has limited commercial control over the program. That mix of high growth and low share fits a Question Mark in the BCG Matrix. The latest public filings still show the value case depends on clinical progress, not near-term scale.
Apeiron Biologics collaboration
Apeiron Biologics adds Evotec SE exposure to specialized biotech innovation, but the payoff is still binary: one clinical win can lift value fast, while a setback can erase it. Public 2025/2026 financials for the Apeiron program are not disclosed, so the collaboration stays hard to underwrite on cash flow alone. Until it shows durable clinical and commercial traction, it remains a Question Mark.
- High upside, but no clear traction yet
- Clinical risk stays the main swing factor
- Commercial scale is still unproven
- Best viewed as optionality, not core cash flow
Chinook Therapeutics program
Chinook Therapeutics fits Question Mark because Evotec’s exposure sat in a collaboration set, but the asset’s route changed after Novartis agreed to buy Chinook in 2023 for $3.2 billion upfront plus up to $1.2 billion in milestones. With ownership and commercialization no longer clear, revenue visibility stays limited. That keeps it far from a stable cash generator.
- 2023 deal value: $3.2 billion upfront
- Up to $1.2 billion in milestones
- Unclear ownership cuts visibility
- Question Mark, not a cash cow
Evotec’s Question Marks: High Upside, Low Proof
Evotec SE’s Question Marks stay high-upside but still unproven. CONBA and Zhejiang JingXin give China reach, while Kazia and Apeiron add oncology and biotech optionality, yet commercial control and cash conversion remain weak. Chinook’s $3.2 billion upfront Novartis deal plus up to $1.2 billion in milestones also cut visibility, so these assets fit as growth bets, not cash cows.
| Asset | Why Question Mark |
|---|---|
| CONBA | China upside, low share |
| Kazia | Oncology growth, weak control |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.